drugset

drugset / Trial / NCT00492388

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

NCT00492388 ↗

Phase 3 Terminated 2 enrolled Pfizer

RandomizedCrossoverQuadruple-blindTreatment

Summary

To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.

Timeline

Start: 2007-06
Primary completion: 2011-08
Completion: 2011-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketamine	Small molecule	—	Intranasal

Indications